ATE292965T1 - Therapeutische anwendung von polymere die gamma- hydroxybutyrat enthalten - Google Patents

Therapeutische anwendung von polymere die gamma- hydroxybutyrat enthalten

Info

Publication number
ATE292965T1
ATE292965T1 AT00963475T AT00963475T ATE292965T1 AT E292965 T1 ATE292965 T1 AT E292965T1 AT 00963475 T AT00963475 T AT 00963475T AT 00963475 T AT00963475 T AT 00963475T AT E292965 T1 ATE292965 T1 AT E292965T1
Authority
AT
Austria
Prior art keywords
oligomers
compositions
polymers
ghb
produce
Prior art date
Application number
AT00963475T
Other languages
English (en)
Inventor
Simon F Williams
David P Martin
Original Assignee
Tepha Inc
Metabolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tepha Inc, Metabolix Inc filed Critical Tepha Inc
Application granted granted Critical
Publication of ATE292965T1 publication Critical patent/ATE292965T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00963475T 1999-09-14 2000-09-14 Therapeutische anwendung von polymere die gamma- hydroxybutyrat enthalten ATE292965T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15384499P 1999-09-14 1999-09-14
US18237100P 2000-02-14 2000-02-14
PCT/US2000/025261 WO2001019361A2 (en) 1999-09-14 2000-09-14 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate

Publications (1)

Publication Number Publication Date
ATE292965T1 true ATE292965T1 (de) 2005-04-15

Family

ID=26850917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00963475T ATE292965T1 (de) 1999-09-14 2000-09-14 Therapeutische anwendung von polymere die gamma- hydroxybutyrat enthalten

Country Status (9)

Country Link
US (1) US6623730B1 (de)
EP (1) EP1212052B1 (de)
JP (1) JP4723143B2 (de)
AT (1) ATE292965T1 (de)
AU (1) AU783104B2 (de)
CA (1) CA2383011C (de)
DE (1) DE60019435T2 (de)
ES (1) ES2240163T3 (de)
WO (1) WO2001019361A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015200B2 (en) * 2000-09-22 2006-03-21 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
CA2525132C (en) 2003-05-08 2011-06-28 Tepha, Inc. Polyhydroxyalkanoate medical textiles and fibers
WO2005007195A1 (en) * 2003-07-08 2005-01-27 Tepha, Inc. Poly-4-hydroxybutyrate matrices for sustained drug delivery
EP1792927B1 (de) 2004-09-22 2013-03-06 Nippon Kayaku Kabushiki Kaisha Neues blockcopolymer, micellenzubereitung und antikrebsmittel, das diese als wirkbestandteil enthält
GB0424885D0 (en) 2004-11-11 2004-12-15 Weatherford Uk Ltd Reaming apparatus
GB0427145D0 (en) * 2004-12-10 2005-01-12 Ketocytonyx Inc Compositions for use in surgery
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
WO2007111211A1 (ja) 2006-03-28 2007-10-04 Nippon Kayaku Kabushiki Kaisha タキサン類の高分子結合体
KR20090009241A (ko) 2006-05-18 2009-01-22 니폰 가야꾸 가부시끼가이샤 포도필로톡신류의 고분자 결합체
EP2080779B1 (de) 2006-11-06 2016-05-18 Nippon Kayaku Kabushiki Kaisha Polymeres derivat eines nucleinsäuremetabolismus-antagonisten
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
JP5504534B2 (ja) * 2007-03-30 2014-05-28 有限会社アーザス ケトン体生成促進剤組成物
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
KR101589582B1 (ko) 2008-03-18 2016-01-28 니폰 가야꾸 가부시끼가이샤 생리활성물질의 고분자량 결합체
US20100029771A1 (en) * 2008-07-31 2010-02-04 Olivier Ameisen Treatment of addictive disorders
WO2010124046A1 (en) 2009-04-23 2010-10-28 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
EP2431403B1 (de) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymerkonjugat aus einer bioaktiven substanz mit einer hydroxidgruppe
CN102781901B (zh) 2010-02-11 2016-08-03 梅塔玻利克斯公司 用于从经遗传修饰的聚羟基链烷酸酯生物质制备单体组分的方法
CN103221054A (zh) 2010-11-17 2013-07-24 日本化药株式会社 新的胞苷类代谢拮抗剂的高分子衍生物
MX355742B (es) * 2011-02-14 2018-04-26 Concert Pharmaceuticals Inc Análogos deuterados del ácido 4-hidroxibutírico.
EP2754682B1 (de) 2011-09-11 2017-06-07 Nippon Kayaku Kabushiki Kaisha Verfahren zur herstellung von blockcopolymer
EP2760911B1 (de) 2011-09-27 2017-11-22 Tepha, Inc. Gesteuerte hydrolyse von poly-4-hydroxybutyrat und copolymeren
CA3026687A1 (en) 2012-03-21 2013-09-26 Galleon Labs Llc Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
BR112014030203B1 (pt) 2012-06-08 2021-10-13 Cj Cheiljedang Corporation Processo para produção de produtos de ácido acrílico de base biológica
ES2774932T3 (es) 2012-11-14 2020-07-23 Cj Cheiljedang Corp Producción de sales de 4-hidroxibutirato utilizando materias primas de base biológica
US20160143867A1 (en) * 2013-06-21 2016-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
US9480780B2 (en) 2013-11-05 2016-11-01 Tepha, Inc. Compositions and devices of poly-4-hydroxybutyrate
WO2016025329A1 (en) 2014-08-15 2016-02-18 Tepha, Inc. Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
CA2969429C (en) 2014-12-11 2020-10-27 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
US20170049807A1 (en) * 2015-08-21 2017-02-23 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
JP2019523758A (ja) * 2016-05-23 2019-08-29 カリフォルニア インスティチュート オブ テクノロジー 神経変性障害を治療するための腸内微生物叢の制御
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
CN111514124B (zh) * 2020-04-13 2021-04-13 上海大学 3-羟基苯乙酸在制备改善心肌梗死后的心室病理性重构和/或心力衰竭的药物中的应用
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1217783B (it) * 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1238344B (it) 1989-10-20 1993-07-13 Sigma Tau Ind Farmaceuti Estere della l-carnitina con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che lo contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
US5563239A (en) 1994-11-09 1996-10-08 Eastman Chemical Company Composition and process for the production of poly(3-hydroxyalkanoates)
US5840331A (en) * 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
US6083729A (en) * 1995-10-26 2000-07-04 Metabolix, Inc. Methods for isolating polyhydroxyalkanoates from plants
AU1671297A (en) 1996-02-13 1997-09-02 Global Art Co. Ltd. Polyester cyclic compounds, their complexes and bonded bodies
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
AU725516B2 (en) 1997-09-19 2000-10-12 Metabolix, Inc. Biological systems for manufacture of polyhydroxyalkanoate polymers containing 4-hydroxyacids
DE69841579D1 (de) * 1997-12-22 2010-05-06 Metabolix Inc Polyhydroxyalkanoatzusammensetzungen mit kontrollierten Abbaugeschwindigkeiten
WO1999035192A1 (en) 1998-01-09 1999-07-15 Metabolix, Inc. Polymer compositions providing low residue levels and methods of use thereof

Also Published As

Publication number Publication date
EP1212052B1 (de) 2005-04-13
CA2383011A1 (en) 2001-03-22
ES2240163T3 (es) 2005-10-16
DE60019435T2 (de) 2006-02-23
AU7488600A (en) 2001-04-17
JP2003509366A (ja) 2003-03-11
WO2001019361A3 (en) 2001-10-04
JP4723143B2 (ja) 2011-07-13
DE60019435D1 (de) 2005-05-19
WO2001019361A2 (en) 2001-03-22
CA2383011C (en) 2008-07-22
EP1212052A2 (de) 2002-06-12
AU783104B2 (en) 2005-09-22
US6623730B1 (en) 2003-09-23

Similar Documents

Publication Publication Date Title
ATE292965T1 (de) Therapeutische anwendung von polymere die gamma- hydroxybutyrat enthalten
JP2003509366A5 (de)
ES2089027T3 (es) Forma de dosificacion transmucosica.
JP2005520778A5 (de)
TW536401B (en) A pharmaceutical composition of N,N-bis(phenylcarbamoylmethyl)dimethylammomum chloride and derivatives for the treatment of pain
ITMI931714A1 (it) Uso del taxol per la produzione di un medicamento per il trattamento delle forme cancerose
EA200501420A1 (ru) Устройство доставки для лекарственной и клеточной терапии
Hurtig Problems with current pharmacologic treatment of Parkinson's disease
JP2005515966A5 (de)
RU2006143659A (ru) Применение ребоксетина для лечения боли
US20150352040A1 (en) Topical peripheral neuro-affective (tpna) therapy
CN1291754C (zh) 局麻药增效延时剂
de Jong Ropivacaine: White knight or dark horse?
RU2010114755A (ru) Фармацевтическое соединение
RU2009101026A (ru) Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии
RU2010118458A (ru) Производное изоксазола для лечения рака
KR960700701A (ko) 파라세타몰 및 l-시스테인 또는 이것의 전구물질을 함유하는 약제조성물(pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof)
IT9086204A1 (it) Metodo per la cura dell'impotenza erettiva maschile
Oettmeier et al. The procaine-base-infusion: 20 years of experience of an alternative use with several therapeutical effects
US20160058752A1 (en) Topical peripheral neuro-affective (tpna) therapy for neuropathic conditions
BRPI0405520A (pt) novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação
WO2001089508A1 (en) Novel long acting, reversible veterinary sedative and analgesic and method of use
Younus et al. Analgesic Options in the Prevention Post? Craniotomy Pain (PCP)
RU2007141393A (ru) Способ лечения спастического и болевого синдромов у пациентов с последствиями позвоночно-спинномозговой травмы
UY26485A1 (es) "pirroles sustituidos"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties